Effects of Pharmacologic Dose of Resveratrol Supplementation on Oxidative/Antioxidative Status Biomarkers in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

Results: Resveratrol supplementation did not significantly affect neither serum MDA, oxLDL, and TAC levels, nor erythrocyte SOD and GSH-Px activities, compared to placebo group (All P>0.05). [...]changes in serum levels of liver enzymes (ALT, AST, GGT, and ALP) were not significant in neither of...

Full description

Saved in:
Bibliographic Details
Published in:Advanced pharmaceutical bulletin Vol. 8; no. 2; pp. 307 - 317
Main Authors: Asghari, Somayyeh, Rafraf, Maryam, Farzin, Laleh, Asghari-Jafarabadi, Mohammad, Ghavami, Seyed-Mostafa, Somi, Mohammad-Hossein
Format: Journal Article
Language:English
Published: Tabriz Tabriz University of Medical Sciences 01-06-2018
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Results: Resveratrol supplementation did not significantly affect neither serum MDA, oxLDL, and TAC levels, nor erythrocyte SOD and GSH-Px activities, compared to placebo group (All P>0.05). [...]changes in serum levels of liver enzymes (ALT, AST, GGT, and ALP) were not significant in neither of the study groups (All P>0.05). Introduction Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, with a prevalence rate of 6-35% in the general population, depending on the assessment methods and the study population.1 Higher prevalences were found among those afflicted with metabolic disorders such as obesity, type 2 diabetes, and metabolic syndrome.1,2 NAFLD represents a spectrum of liver diseases from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH), and fibrosis, which may progress to cirrhosis and even hepatocellular carcinoma.3 Insulin resistance and oxidative stress are among the major important risk factors for this disease, and current therapeutic approaches to NAFLD include strategies that could modify these risk factors.4 Insulin resistance leads to increased lipolysis and hepatic uptake of free fatty acids (FFA) and enhances hepatic triglyceride synthesis and accumulation.5 The excessive offer of lipids to the mitochondria would promote production of reactive oxygen species (ROS), which contribute to lipid peroxidation and eventual oxidative stress.6,7 The most remarkable consequence of oxidative stress is the oxidation of lipids, proteins, DNA, and enzymes, leading to cellular damage and acceleration of cell death induced by apoptosis and necrosis.8 Oxidative stress is considered of primary importance in the disease progression from simple steatosis to steatohepatitis and liver damage.9 Lipid peroxidation and ROS can also lead to depletion of nonenzymatic antioxidants as well as antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). In another study on fructose-fed rats, resveratrol induced a significant reduction in TBARS levels, indicating a possible role of resveratrol in free radical inactivation.45 There is increasing evidence that antioxidant-rich dietary patterns, induce significant reductions in LDL oxidation.46 A recent trial performed in hypercholesterolemic patients demonstrated that resveratrol at a dose of 8 mg/d significantly reduced serum ox-LDL during 6 months.24 The evidence suggests that resveratrol exerts its antioxidant activities by scavenging ROS and reactive nitrogen species (RNS) and secondary organic radicals formed as a result of the reaction of biomolecules with ROS and RNS.47 The increased lipid peroxidation might be explained by increased oxidative stress as a result of the antioxidant depletion.48 LDL and other biomolecules are protected from oxidative damage by the action of blood antioxidant capacity.49 TAC is an indicator of the overall protection of antioxidants against oxidative stress in body fluids and cell components.50 Plasma antioxidant status includes enzymatic and nonenzymatic antioxidant activities.49 Enzymatic antioxidants like SOD and GSHPx are the first line of defense against ROS and play a vital role in scavenging free radicals. In this study, there were no significant differences in daily dietary intakes of macronutrients and known antioxidants between the two groups, by the end of the study. [...]dietary factors are not likely to have confounded our results.
AbstractList Results: Resveratrol supplementation did not significantly affect neither serum MDA, oxLDL, and TAC levels, nor erythrocyte SOD and GSH-Px activities, compared to placebo group (All P>0.05). [...]changes in serum levels of liver enzymes (ALT, AST, GGT, and ALP) were not significant in neither of the study groups (All P>0.05). Introduction Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, with a prevalence rate of 6-35% in the general population, depending on the assessment methods and the study population.1 Higher prevalences were found among those afflicted with metabolic disorders such as obesity, type 2 diabetes, and metabolic syndrome.1,2 NAFLD represents a spectrum of liver diseases from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH), and fibrosis, which may progress to cirrhosis and even hepatocellular carcinoma.3 Insulin resistance and oxidative stress are among the major important risk factors for this disease, and current therapeutic approaches to NAFLD include strategies that could modify these risk factors.4 Insulin resistance leads to increased lipolysis and hepatic uptake of free fatty acids (FFA) and enhances hepatic triglyceride synthesis and accumulation.5 The excessive offer of lipids to the mitochondria would promote production of reactive oxygen species (ROS), which contribute to lipid peroxidation and eventual oxidative stress.6,7 The most remarkable consequence of oxidative stress is the oxidation of lipids, proteins, DNA, and enzymes, leading to cellular damage and acceleration of cell death induced by apoptosis and necrosis.8 Oxidative stress is considered of primary importance in the disease progression from simple steatosis to steatohepatitis and liver damage.9 Lipid peroxidation and ROS can also lead to depletion of nonenzymatic antioxidants as well as antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). In another study on fructose-fed rats, resveratrol induced a significant reduction in TBARS levels, indicating a possible role of resveratrol in free radical inactivation.45 There is increasing evidence that antioxidant-rich dietary patterns, induce significant reductions in LDL oxidation.46 A recent trial performed in hypercholesterolemic patients demonstrated that resveratrol at a dose of 8 mg/d significantly reduced serum ox-LDL during 6 months.24 The evidence suggests that resveratrol exerts its antioxidant activities by scavenging ROS and reactive nitrogen species (RNS) and secondary organic radicals formed as a result of the reaction of biomolecules with ROS and RNS.47 The increased lipid peroxidation might be explained by increased oxidative stress as a result of the antioxidant depletion.48 LDL and other biomolecules are protected from oxidative damage by the action of blood antioxidant capacity.49 TAC is an indicator of the overall protection of antioxidants against oxidative stress in body fluids and cell components.50 Plasma antioxidant status includes enzymatic and nonenzymatic antioxidant activities.49 Enzymatic antioxidants like SOD and GSHPx are the first line of defense against ROS and play a vital role in scavenging free radicals. In this study, there were no significant differences in daily dietary intakes of macronutrients and known antioxidants between the two groups, by the end of the study. [...]dietary factors are not likely to have confounded our results.
Purpose: Despite a proposed role for oxidative stress in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), antioxidant approaches have not been sufficiently investigated in human NAFLD management. Resveratrol has been reported to possess a wide range of biological functions, including antioxidant activities. This study aimed to evaluate the effects of resveratrol supplementation on oxidative/anti-oxidative status in patients with NAFLD. Methods: This randomized, double-blind, placebo-controlled clinical trial was conducted on 60 patients with NAFLD (males and females) aged 20 to 60 years, and body mass index (BMI) of 25-35 kg/m2. Subjects were randomly assigned to receive a daily dose of 600 mg resveratrol (2×300 mg pure trans-resveratrol capsules; n=30) or placebo capsules (n=30) for 12 wk. Fasting blood samples, anthropometric measurements, and dietary intakes were collected for all patients at baseline and at the end of the trial. Oxidative stress was evaluated by measurement of serum malondialdehyde (MDA), oxidized low-density lipoprotein (ox-LDL), total antioxidant capacity (TAC), and erythrocyte superoxide dismutase (SOD) as well as glutathione peroxidase (GSH-Px) activities. Changes in the outcomes were analyzed using analysis of covariance (ANCOVA). Results: Resveratrol supplementation did not significantly affect neither serum MDA, ox-LDL, and TAC levels, nor erythrocyte SOD and GSH-Px activities, compared to placebo group (All P>0.05). Moreover, changes in serum levels of liver enzymes (ALT, AST, GGT, and ALP) were not significant in neither of the study groups (All P>0.05). Conclusion: Resveratrol supplementation did not modify oxidative/anti-oxidative status in patients with NAFLD.
Purpose: Despite a proposed role for oxidative stress in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), antioxidant approaches have not been sufficiently investigated in human NAFLD management. Resveratrol has been reported to possess a wide range of biological functions, including antioxidant activities. This study aimed to evaluate the effects of resveratrol supplementation on oxidative/anti-oxidative status in patients with NAFLD. Methods: This randomized, double-blind, placebo-controlled clinical trial was conducted on 60 patients with NAFLD (males and females) aged 20 to 60 years, and body mass index (BMI) of 25-35 kg/m2. Subjects were randomly assigned to receive a daily dose of 600 mg resveratrol (2×300 mg pure trans-resveratrol capsules; n=30) or placebo capsules (n=30) for 12 wk. Fasting blood samples, anthropometric measurements, and dietary intakes were collected for all patients at baseline and at the end of the trial. Oxidative stress was evaluated by measurement of serum malondialdehyde (MDA), oxidized low-density lipoprotein (ox-LDL), total antioxidant capacity (TAC), and erythrocyte superoxide dismutase (SOD) as well as glutathione peroxidase (GSH-Px) activities. Changes in the outcomes were analyzed using analysis of covariance (ANCOVA). Results: Resveratrol supplementation did not significantly affect neither serum MDA, ox-LDL, and TAC levels, nor erythrocyte SOD and GSH-Px activities, compared to placebo group (All P>0.05). Moreover, changes in serum levels of liver enzymes (ALT, AST, GGT, and ALP) were not significant in neither of the study groups (All P>0.05). Conclusion: Resveratrol supplementation did not modify oxidative/anti-oxidative status in patients with NAFLD.
Author Asghari-Jafarabadi, Mohammad
Farzin, Laleh
Ghavami, Seyed-Mostafa
Somi, Mohammad-Hossein
Asghari, Somayyeh
Rafraf, Maryam
AuthorAffiliation 6 Liver and Gastrointestinal Diseases Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran
1 Students’ Research Committee, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran
2 Nutrition Research Center, Department of Community Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran
5 Department of Radiology, Paramedical school, Tabriz University of Medical Sciences, Tabriz, Iran
4 Department of Statistics and Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran
3 Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
AuthorAffiliation_xml – name: 4 Department of Statistics and Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran
– name: 3 Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
– name: 2 Nutrition Research Center, Department of Community Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran
– name: 1 Students’ Research Committee, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran
– name: 5 Department of Radiology, Paramedical school, Tabriz University of Medical Sciences, Tabriz, Iran
– name: 6 Liver and Gastrointestinal Diseases Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran
Author_xml – sequence: 1
  givenname: Somayyeh
  surname: Asghari
  fullname: Asghari, Somayyeh
– sequence: 2
  givenname: Maryam
  surname: Rafraf
  fullname: Rafraf, Maryam
– sequence: 3
  givenname: Laleh
  surname: Farzin
  fullname: Farzin, Laleh
– sequence: 4
  givenname: Mohammad
  surname: Asghari-Jafarabadi
  fullname: Asghari-Jafarabadi, Mohammad
– sequence: 5
  givenname: Seyed-Mostafa
  surname: Ghavami
  fullname: Ghavami, Seyed-Mostafa
– sequence: 6
  givenname: Mohammad-Hossein
  surname: Somi
  fullname: Somi, Mohammad-Hossein
BookMark eNpVksFuGyEQhldVqiZNc-wdqdeuAyywbA-VHCdpI0WNlaRnxMJgk-LFhbXV9Bn7UMVxWikICWb4-WZA_9vqYIgDVNV7gieEk5ac6nU_oZjICW7Eq-qIUk7qtsHyYLensuZSksPqJGffY8ZaKklH3lSHDca0KeOo-nPhHJgxo-jQfKnTSpsY4sIbdB4z7LK3kLeQ9JhiQHeb9TrACoZRjz4OqMybX96WYAun06Hk_kXorkg2GZ35uNLpB6SM_IC-xUEHE5cxlAKXehwf0XURJ3TuM-hSb14uF3r-hKboVg82rvxvsB9LM5s-QH0W_FCiedAG-ljP4rBrK4BF98nr8K567XTIcPK8HlffLy_uZ1_r65svV7PpdW2YJGPtOkNoD4SJruugbS1xjmHWcAmMccm5dIa7llgmDCOMGw2m67A1lurWMd4cV1d7ro36Qa2TL098VFF79ZSIaaF0Gr0JoAwwySg1XBjMpGA9axtrORWmE05oVlif96z1pl-BNeX1SYcX0Jcng1-qRdwqgZlgFBfAh2dAij83kEf1EDep_HNWFHedZKIRoqjqvcqkmHMC978CwerJS6p4Se28pIqXmr9MkcFL
CitedBy_id crossref_primary_10_1021_acsnano_1c02158
crossref_primary_10_3390_nu12082435
crossref_primary_10_1155_2019_4619865
crossref_primary_10_1080_01635581_2020_1767166
crossref_primary_10_1186_s12906_021_03381_4
crossref_primary_10_3390_antiox11050975
crossref_primary_10_1016_j_ctim_2019_102290
crossref_primary_10_2174_1871530319666191116112950
crossref_primary_10_3390_ijms25073746
crossref_primary_10_3390_ph15080957
crossref_primary_10_1155_2022_9233650
crossref_primary_10_1186_s12944_020_1198_x
crossref_primary_10_1016_j_ctcp_2020_101281
crossref_primary_10_3390_ijms25020747
crossref_primary_10_1002_14651858_CD013157_pub2
crossref_primary_10_3390_antiox13040480
crossref_primary_10_1016_j_phrs_2022_106414
crossref_primary_10_1002_ptr_7719
crossref_primary_10_1016_j_biopha_2024_116432
crossref_primary_10_3390_ijms22116110
crossref_primary_10_3390_nu13030933
crossref_primary_10_1097_MD_0000000000024884
crossref_primary_10_1039_C9FO01075K
crossref_primary_10_1097_TIN_0000000000000314
crossref_primary_10_3390_ph13100285
crossref_primary_10_1080_17474124_2021_1949289
crossref_primary_10_3389_fonc_2021_664380
crossref_primary_10_1016_j_intimp_2021_107426
crossref_primary_10_1007_s00044_024_03267_3
crossref_primary_10_1136_postgradmedj_2019_136415
crossref_primary_10_3390_nu14122509
crossref_primary_10_1007_s10815_019_01461_6
crossref_primary_10_1097_MEG_0000000000001485
crossref_primary_10_1080_13813455_2020_1764045
Cites_doi 10.1017/S0007114511002753
10.1016/j.bbadis.2014.11.012
10.1371/journal.pone.0161792
10.1016/j.clinbiochem.2010.04.003
10.1007/s00418-011-0847-6
10.3390/ijms161125942
10.1177/0960327110383625
10.1155/2013/714653
10.1016/s0165-0327(00)00199-3
10.1016/j.bbrc.2003.08.105
10.1155/2015/317348
10.1155/2012/947575
10.3748/wjg.v20.i23.7366
10.1016/j.phrs.2012.05.003
10.1111/j.1572-0241.2005.41500.x
10.3390/ijms141020704
10.1179/135100009X466131
10.1016/j.cbpa.2009.04.282
10.1097/TA.0b013e3181f30fb0
10.1097/WOX.0b013e3182439613
10.1002/lt.21405
10.1042/BST0351156
10.1089/met.2014.0082
10.1016/j.jnutbio.2013.09.001
10.2337/dc16-0499
10.3109/00365521.2015.1107620
10.2337/db12-0975
10.1111/j.1365-2036.2008.03710.x
10.1016/j.biochi.2011.08.005
10.1016/j.ejphar.2004.02.031
10.1038/nature05354
10.1016/j.dld.2014.11.015
10.1210/jc.2010-0482
10.1111/j.1365-2036.2011.04724.x
10.1016/j.jhep.2011.08.025
10.1155/2016/9737483
10.1016/j.jnutbio.2012.06.019
10.2478/acb-2014-0006
10.1016/j.cmet.2012.09.015
10.2174/138161210790883561
10.1186/1743-7075-11-35
10.3945/ajcn.2009.28435
10.4254/wjh.v7.i10.1325
10.1017/S0007114511000316
10.1111/j.1749-6632.2010.05844.x
10.1016/j.nutres.2014.09.005
10.2174/0929867311320100009
10.5829/idosi.wasj.2012.18.08.754
10.1002/hep.25762
10.1016/j.cell.2006.11.013
10.1177/0960327110383640
10.1155/2011/525094
10.1016/j.cmet.2012.04.003
10.1002/mnfr.200500003
10.4254/wjh.v7.i11.1450
10.1002/mnfr.201100673
10.1016/j.cgh.2014.02.024
10.1007/s00535-013-0758-5
10.1016/j.arabjc.2010.06.049
ContentType Journal Article
Copyright 2018. This work is published under https://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2018 The Authors. 2018
Copyright_xml – notice: 2018. This work is published under https://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2018 The Authors. 2018
DBID AAYXX
CITATION
8AO
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
CWDGH
DWQXO
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
5PM
DOA
DOI 10.15171/apb.2018.036
DatabaseName CrossRef
ProQuest Pharma Collection
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Middle East & Africa Database
ProQuest Central Korea
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central
Middle East & Africa Database
ProQuest One Academic UKI Edition
ProQuest Central Essentials
ProQuest Central Korea
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Pharma Collection
ProQuest One Academic
ProQuest Central China
DatabaseTitleList Publicly Available Content Database


Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2251-7308
EndPage 317
ExternalDocumentID oai_doaj_org_article_ce48422c56c04864b473dd526c96f6a4
10_15171_apb_2018_036
GroupedDBID 3V.
5VS
8AO
AAYXX
ABDBF
ABUWG
ADBBV
AEGXH
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
BPHCQ
CCPQU
CITATION
CWDGH
DIK
EOJEC
GROUPED_DOAJ
GX1
HYE
IPNFZ
KQ8
M~E
OBODZ
OK1
PIMPY
PQQKQ
PROAC
RIG
RNS
RPM
TUS
AZQEC
DWQXO
PQEST
PQUKI
PRINS
5PM
ID FETCH-LOGICAL-c481t-f9c12be146999e77d1ff404358e4458558fc5f71d46c4145caec990dcd2a7f453
IEDL.DBID RPM
ISSN 2228-5881
IngestDate Tue Oct 22 15:11:39 EDT 2024
Mon May 06 17:43:24 EDT 2024
Thu Oct 10 19:13:55 EDT 2024
Fri Aug 23 02:01:28 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c481t-f9c12be146999e77d1ff404358e4458558fc5f71d46c4145caec990dcd2a7f453
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046420/
PMID 30023333
PQID 2099846366
PQPubID 2032008
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_ce48422c56c04864b473dd526c96f6a4
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6046420
proquest_journals_2099846366
crossref_primary_10_15171_apb_2018_036
PublicationCentury 2000
PublicationDate 20180601
PublicationDateYYYYMMDD 2018-06-01
PublicationDate_xml – month: 6
  year: 2018
  text: 20180601
  day: 1
PublicationDecade 2010
PublicationPlace Tabriz
PublicationPlace_xml – name: Tabriz
PublicationTitle Advanced pharmaceutical bulletin
PublicationYear 2018
Publisher Tabriz University of Medical Sciences
Publisher_xml – name: Tabriz University of Medical Sciences
References R60
R20
R23
R22
R25
R24
R27
R26
R29
R28
R1
Kavas GO (R21) 2013; 22
R2
R3
R4
R5
R6
R7
R8
R9
R30
R32
R31
R34
R33
R36
R35
R38
R37
R39
R41
R40
R43
R42
R45
R44
R47
R46
R49
R48
R50
R52
R51
R10
R54
R53
R12
R56
R11
R55
R14
R58
R13
R57
R16
R15
R59
R18
R17
R19
References_xml – ident: R16
  doi: 10.1017/S0007114511002753
– ident: R54
  doi: 10.1016/j.bbadis.2014.11.012
– ident: R23
  doi: 10.1371/journal.pone.0161792
– ident: R7
  doi: 10.1016/j.clinbiochem.2010.04.003
– ident: R38
  doi: 10.1007/s00418-011-0847-6
– ident: R13
  doi: 10.3390/ijms161125942
– ident: R60
  doi: 10.1177/0960327110383625
– ident: R43
  doi: 10.1155/2013/714653
– ident: R26
  doi: 10.1016/s0165-0327(00)00199-3
– ident: R53
  doi: 10.1016/j.bbrc.2003.08.105
– ident: R49
  doi: 10.1155/2015/317348
– ident: R10
  doi: 10.1155/2012/947575
– ident: R14
  doi: 10.3748/wjg.v20.i23.7366
– ident: R45
  doi: 10.1016/j.phrs.2012.05.003
– ident: R12
  doi: 10.1111/j.1572-0241.2005.41500.x
– ident: R9
  doi: 10.3390/ijms141020704
– volume: 22
  start-page: 151
  year: 2013
  ident: R21
  article-title: The effects of resveratrol on oxidant/antioxidant systems and their cofactors in rats
  publication-title: Adv Clin Exp Med
  contributor:
    fullname: Kavas GO
– ident: R58
  doi: 10.1179/135100009X466131
– ident: R33
  doi: 10.1016/j.cbpa.2009.04.282
– ident: R50
  doi: 10.1097/TA.0b013e3181f30fb0
– ident: R48
  doi: 10.1097/WOX.0b013e3182439613
– ident: R57
  doi: 10.1002/lt.21405
– ident: R19
  doi: 10.1042/BST0351156
– ident: R27
  doi: 10.1089/met.2014.0082
– ident: R35
  doi: 10.1016/j.jnutbio.2013.09.001
– ident: R55
  doi: 10.2337/dc16-0499
– ident: R39
  doi: 10.3109/00365521.2015.1107620
– ident: R37
  doi: 10.2337/db12-0975
– ident: R4
  doi: 10.1111/j.1365-2036.2008.03710.x
– ident: R8
  doi: 10.1016/j.biochi.2011.08.005
– ident: R52
  doi: 10.1016/j.ejphar.2004.02.031
– ident: R30
  doi: 10.1038/nature05354
– ident: R42
  doi: 10.1016/j.dld.2014.11.015
– ident: R44
  doi: 10.1210/jc.2010-0482
– ident: R1
  doi: 10.1111/j.1365-2036.2011.04724.x
– ident: R6
  doi: 10.1016/j.jhep.2011.08.025
– ident: R22
  doi: 10.1155/2016/9737483
– ident: R17
  doi: 10.1016/j.jnutbio.2012.06.019
– ident: R47
  doi: 10.2478/acb-2014-0006
– ident: R36
  doi: 10.1016/j.cmet.2012.09.015
– ident: R46
  doi: 10.2174/138161210790883561
– ident: R20
  doi: 10.1186/1743-7075-11-35
– ident: R29
  doi: 10.3945/ajcn.2009.28435
– ident: R11
  doi: 10.4254/wjh.v7.i10.1325
– ident: R56
  doi: 10.1017/S0007114511000316
– ident: R28
  doi: 10.1111/j.1749-6632.2010.05844.x
– ident: R41
  doi: 10.1016/j.nutres.2014.09.005
– ident: R51
  doi: 10.2174/0929867311320100009
– ident: R25
  doi: 10.5829/idosi.wasj.2012.18.08.754
– ident: R3
  doi: 10.1002/hep.25762
– ident: R31
  doi: 10.1016/j.cell.2006.11.013
– ident: R59
  doi: 10.1177/0960327110383640
– ident: R34
  doi: 10.1155/2011/525094
– ident: R32
  doi: 10.1016/j.cmet.2012.04.003
– ident: R18
  doi: 10.1002/mnfr.200500003
– ident: R2
  doi: 10.4254/wjh.v7.i11.1450
– ident: R24
  doi: 10.1002/mnfr.201100673
– ident: R40
  doi: 10.1016/j.cgh.2014.02.024
– ident: R5
  doi: 10.1007/s00535-013-0758-5
– ident: R15
  doi: 10.1016/j.arabjc.2010.06.049
SSID ssib044728191
ssj0000603415
Score 2.3326948
Snippet Results: Resveratrol supplementation did not significantly affect neither serum MDA, oxLDL, and TAC levels, nor erythrocyte SOD and GSH-Px activities, compared...
Purpose: Despite a proposed role for oxidative stress in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), antioxidant approaches have not been...
Purpose: Despite a proposed role for oxidative stress in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), antioxidant approaches have not been...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 307
SubjectTerms Clinical trial
Double-blind studies
Insulin resistance
Lipids
Liver cirrhosis
Nonalcoholic fatty liver disease
Oxidation
Oxidative stress
Resveratrol supplementation
Rodents
Studies
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ1Lj9MwEMct2BMXxFOUXZAPqKeGJuk4cbm12632gJZqKRK3yPFDROomq6ZF2_2MfChm4vSRExekXPKQ7GQm9oz998-MfcL8LLS07ANbfxmAHUGgFCjMWgXR13PMi2i84_p7evNTzq4Ik3PY6os0YR4P7D_cUFuQEMdaJJrocJBDOjJGxIkeJy5RngQaypNkCj0JIKUJougw2hImITbXpGekEY9ASBm1wE0RpdFQ3eek8pKfwwbVfOygGo5_J_jsSidP-qL5C_a8DSL5xFf-JXtiy1esv_AU6t2AL4-LquoB7_PFkU-9e83-eGJxzSt3eqfQfFbVlq7e2vo3wZbX1Yo32356iTnZkOPx7aEwDS98OCGt5P6MU-C6rfm0qO5I9LOueVHyGwr1m214sYC52mx2_CtpQfjMTw3xhSe71l_4hN-q0lR3xaM1A6zMNl_ZYIpxMJ4taLg_r4JLL61fWcOX9O-8YT_mV8vL66Dd1CHQIKNN4MY6inOLDTSGpjZNTeQcEX6EtACYuwjptHBpZCDREIHQymrsMY02sUodiNFbdlZWpX3HOJH-Yyf1GPIRmNCNnQq1FU7aGLQTrsf6e0tm957dkVHOQybP0OQZmTxDk_fYlOx8eIiQ280FdMSsdcTsX47YYxd7L8nadqDOaGGyJCYblpF2PKdTWPdOWfxqON8JTTvH4fv_Ubtz9oze1ovcLtjZZr21H9jT2mw_Nn_OX2u2H20
  priority: 102
  providerName: Directory of Open Access Journals
Title Effects of Pharmacologic Dose of Resveratrol Supplementation on Oxidative/Antioxidative Status Biomarkers in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
URI https://www.proquest.com/docview/2099846366
https://pubmed.ncbi.nlm.nih.gov/PMC6046420
https://doaj.org/article/ce48422c56c04864b473dd526c96f6a4
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELboHtBeEE9RWFY-oJ6a5jVOXG59bLUHWKKlSNyixA82UptUTYsov5EfhcdJdjdXpFxsJ7KjGY9nxp8_E_LRxGeewmMfxvpzB1QITpZBZqJWhuzruYmLMN9x_S2--cGXV0iTw7qzMBa0L_JiUm62k7K4s9jK3Va4HU7MTb4sItyPCzx3QAbGN-yH6AAx7g3594kWL_KMpUYoIyY7HMa533JtMj_23WyXI8CLT4wpPydPQ1zEwjDsLVOWzb_ngvYBlI9WpNVz8qx1JemsGfIL8kSVL8koabioT2O6fjhaVY_piCYPLNWnV-Rvw1tc00o_bikEXVa1wtpbVf9CyuV9taH28s8GaI6SpOb5-ruQljXcnSFisitRdF-PNZ0X1RahP_uaFiW9QYffXsZrOlhlh8OJfkZECF02G0Q0afhd6090Rm-zUlbb4o-SYzOYY75Rztx4w6aUYNI_r5xFA7DfKEnXOINek--rq_Xi2mmvdnAEcP_g6Knwg1wZM20cVBXH0tcaeX4YVwAmgmFcC6ZjX0IkwAcmMiXMuimFDLJYAwvfkLOyKtVbQpHvP9BcTCEPQXp6qjNPKKa5CkBopodk1Eky3TUMHilGPij91Eg_RemnRvpDMkc537-ExNu2otr_TFv1S4UCDkEgWCSQrBByiEMpWRCJaaSjDIbkotOStLUGdYrHkzkys5k-4p7m9Drrtxjlt2zfrbK_--8v35Nz_MUG33ZBzg77o_pABrU8XtoMxKWdP_8AejwhTw
link.rule.ids 230,315,729,782,786,866,887,2108,27935,27936,53803,53805
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLWYQYLZ8B5RGMAL1FXT5mEnLrs-piqiU6KhSOwsxw-I1CZV0yLKN_JR-OYxM9mOlI3jRI6V4-t7fY-PEfpo4zNXw7YPa_2ZQ3RAHCGIsFErBfX1xMZFsN4x_xYtf7DpJcjk0GYvTEnal0naz9abfpb-KrmV240cNDyxQXw1CSEf57uDE_TQjlc3aAfphESQHfJullrc0LW2GsiMsNzhUMa8Wm2TepE3ENsEKF6sb435GXoUwDQWBEFroir1_FtOaJtCeWdOmj29Z2-eoSe1E4pHVfVz9EBnL1A3rlSsjz28ut2UVfRwF8e3-tbHl-hfpXhc4NzcrUklnuaFhrvXuvgNYs27fI3LY0MrijpgANvr659UlXrjgxFwLZsSBsf3UOBxmm-ANLQrcJrhJYQK5TG-toGZ2O-PeAFcEjytUks4rpRhi094hK9FpvJN-lernv2YQ7LWztj60bYUQ7ogyZ1JRc1fa4VXMPZeoe-zy9Vk7tSHQjiSMG_vmKH0_ERbA29dWx1FyjMGFIIo04TY2IcyI6mJPEVCSTxCpdDSzrhKKl9EhtDgHJ1meaZfIwwnBfiGySFJAqJcMzTClZoapn0iDTUd1G0QwLeV9geHmAlQwy1qOKCGW9R00BjwcfMQSHaXN_LdT17_ai41YcT3JQ0lyByShESBUtQP5TA0oSAddNGgi9d2pOCwsZmBppttI2ohrtVYu8YCrdQJr4H15t5vfkCP56urBV98Xn55i86guxVL7gKd7ncH_Q6dFOrwvhx9_wFvUjXb
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLbYkKa9wLiJwjb8gPrUNDc7cXnrZdUQo0SjSLxZji8QqU2qpkWU38iPmk-SdssrSHlJ7Mix8vn4HPvzdxB6b-MzT8OxD2v9mUN0SBwhiLBRKwX19dTGRbDecf01nn1nkyuQyTmk-qpI-zLN-vli2c-znxW3crWU7p4n5iafxxHsxwWeu1LGPUKP7Zj1aDtQJySGHSL_sNziRZ6110BohCUPhzLmN4qb1I99V6xSoHmxvjXop-gkhKksDMPWZFVp-rcc0TaN8sG8NH36Hz06Q08aZxQP6yrP0COdP0fdpFaz3vXw_P5wVtnDXZzc61zvXqC_tfJxiQvzsCSTeFKUGp7e6vIXiDaviwWu0ofWVHXAArbXl9-ZqnTH3SFwLvd3GBzgbYlHWbEE8tC6xFmOZxAyVOl8bQNTsdns8A1wSvCk3mLCSa0QW37AQ3wrclUssz9a9ezHbNOFdkbWn7Z3CWwbpIUzrin6C63wHMbgS_RtejUfXztNcghHEuZvHDOQfpBqa-iti6vjWPnGgFIQZZoQGwNRZiQ1sa9IJIlPqBRa2plXSRWI2BAavkLHeZHr1whDxoDAMDkgaUiUZwZGeFJTw3RApKGmg7p7FPBVrQHCIXYC5HCLHA7I4RY5HTQCjBwqgXR39aBY_-DN7-ZSE0aCQNJIgtwhSUkcKkWDSA4iEwnSQed7hPHGnpQcDjgz0HazbcQt1LUaa5dYsFV64Q243vzzm-_QSTKZ8puPs09v0Sn0tibLnaPjzXqrL9BRqbaX1QC8A_bmOFs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+Pharmacologic+Dose+of+Resveratrol+Supplementation+on+Oxidative%2FAntioxidative+Status+Biomarkers+in+Nonalcoholic+Fatty+Liver+Disease+Patients%3A+A+Randomized%2C+Double-Blind%2C+Placebo-+Controlled+Trial&rft.jtitle=Advanced+pharmaceutical+bulletin&rft.au=Asghari%2C+Somayyeh&rft.au=Rafraf%2C+Maryam&rft.au=Farzin%2C+Laleh&rft.au=Asghari-Jafarabadi%2C+Mohammad&rft.date=2018-06-01&rft.pub=Tabriz+University+of+Medical+Sciences&rft.issn=2228-5881&rft.eissn=2251-7308&rft.volume=8&rft.issue=2&rft.spage=307&rft.epage=317&rft_id=info:doi/10.15171%2Fapb.2018.036&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2228-5881&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2228-5881&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2228-5881&client=summon